Piper Jaffray Companies restated their overweight rating on shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP) in a research note released on Friday morning, Marketbeat.com reports. The firm currently has a $22.00 price objective on the stock.
Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Gemphire Therapeutics from a hold rating to a strong-buy rating and set a $22.00 price objective for the company in a research report on Thursday, August 3rd. Canaccord Genuity set a $31.00 price objective on Gemphire Therapeutics and gave the company a buy rating in a research report on Wednesday, July 26th. Jefferies Group LLC boosted their price objective on Gemphire Therapeutics to $32.00 and gave the company a buy rating in a research report on Tuesday, August 1st. Finally, HC Wainwright began coverage on Gemphire Therapeutics in a research report on Thursday, August 31st. They set a buy rating and a $21.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Gemphire Therapeutics currently has a consensus rating of Buy and an average price target of $22.00.
Gemphire Therapeutics (NASDAQ GEMP) traded down 2.85% during midday trading on Friday, hitting $9.90. The stock had a trading volume of 3,575 shares. Gemphire Therapeutics has a one year low of $7.20 and a one year high of $21.59. The firm’s market cap is $105.20 million. The stock has a 50-day moving average price of $9.67 and a 200 day moving average price of $9.67.
Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.28). On average, analysts predict that Gemphire Therapeutics will post ($3.00) earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC acquired a new position in Gemphire Therapeutics during the 1st quarter worth $184,000. Northpointe Capital LLC acquired a new position in Gemphire Therapeutics during the 2nd quarter worth $3,472,000. Cambridge Investment Research Advisors Inc. boosted its position in Gemphire Therapeutics by 1.7% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 153,064 shares of the company’s stock worth $1,959,000 after acquiring an additional 2,500 shares during the period. Vanguard Group Inc. boosted its position in Gemphire Therapeutics by 137.6% during the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after acquiring an additional 17,892 shares during the period. Finally, GM Advisory Group Inc. acquired a new position in Gemphire Therapeutics during the 2nd quarter worth $457,000. Institutional investors and hedge funds own 32.06% of the company’s stock.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
What are top analysts saying about Gemphire Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gemphire Therapeutics Inc. and related companies.